Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Major Cardiovascular Events

Fixed-dose combination therapy (the polypill) was developed to reduce treatment complexity and improve adherence to evidence-based cardiovascular therapies. This review evaluates contemporary evidence for its effects on major cardiovascular events and cardiovascular mortality across primary prevention, secondary prevention, and emerging heart failure applications, while addressing implementation barriers and remaining evidence gaps.

Early pharmacodynamic and adherence trials established that co-formulation preserves the effects of individual components and improves medication adherence. Event-powered trials subsequently demonstrated clinical benefit: PolyIran and TIPS-3 reduced major cardiovascular events in predominantly primary prevention population, whereas SECURE reduced recurrent events after myocardial infarction. Individual-participant and aggregate-data meta-analyses showed relative reductions of approximately 20% to 40% in composite cardiovascular outcomes and a reduction in cardiovascular mortality, with larger benefits among patients with greater adherence and in aspirin-containing strategies. POLY-HF extended the approach to heart failure with reduced ejection fraction, improving left ventricular ejection fraction and uptake of guideline-directed therapy; reductions in heart failure events were secondary findings that require confirmation in larger outcome trials. These findings supports fixed-dose combination therapy as an effective strategy for improving adherence and reducing cardiovascular events, with a cardiovascular mortality benefit supported by pooled analyses. Its greatest potential may be in high-risk populations and resource-limited settings, where treatment complexity impedes implementation. Broader adoption will require formulation standardization, sufficient dosing flexibility, longer-term safety data, and effective integration into clinical guidelines and health systems.